Cambridge, MA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Alopexx, Inc., a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention ...

Alopexx, Inc., a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal, and parasitic ...

HYDERABAD: Bharat Biotech International Limited (BBIL) on Tuesday announced the rollout of HILLCHOL (BBV131), a novel ...

HYDERABAD: Hyderabad-based vaccine manufacturer Bharat Biotech International Limited (BBIL) on Tuesday announced the launch ...

Alopexx, Inc., a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal, and ...

Hyderabad: Bharat Biotech International Limited (BBIL) on Tuesday said it has bagged approval from the Indian drug regulator, Drugs Controller General of India, for manufacturing and marketing its ...

Bharat Biotech International Limited announced the release of HILLCHOL, an innovative single-strain oral cholera vaccine. Developed under license from Hilleman Laboratories, HILLCHOL aims to ...

Global demand for Oral Cholera Vaccines (OCVs) exceeds 100 million doses annually, making them crucial for cholera control. Globally, there is a shortage of OCVs as there is only one manufacturer.

Bharat Biotech has teamed up with Alopexx, Inc. to co-develop and commercialize AV0328, a broad-spectrum antimicrobial ...

HYDERABAD, Aug 27 (Reuters) - India's Bharat Biotech said on Tuesday its oral ... (to develop a vaccine), the production capacity is limited. If you have a single strain, it can give you better ...

Bharat Biotech International Ltd on Tuesday announced the launch of Hillchol, a novel single-strain oral cholera vaccine. A press release from the vaccine maker said Hillchol (BBV131) was ...